-transparent.png){kind=logo}
Targetable, injectable vectors would greatly facilitate the development of in vivo therapy strategies. Viral and nonviral vectors can be targeted through ligand-receptor interactions, but protease-substrate interactions have not previously been exploited for vector targeting. Epidermal growth factor (EGF) was fused to a retroviral envelope glycoprotein via a cleavable linker comprising a factor Xa protease recognition signal. Vector particles displaying the cleavable EGF domain could bind to EGF receptors on human cells but did not transfer their genes until they were cleaved by factor Xa protease, whereupon gene delivery proceeded normally. Proteolytic activation of receptor-targeted vectors can therefore provide the basis for a novel two-step targeting strategy that may facilitate efficient targeted in vivo delivery of therapeutic genes.
B H Nilson, and
F J Morling, and
F L Cosset, and
S J Russell
November 1994,
Science (New York, N.Y.),
B H Nilson, and
F J Morling, and
F L Cosset, and
S J Russell
November 2006,
Molecular therapy : the journal of the American Society of Gene Therapy,
B H Nilson, and
F J Morling, and
F L Cosset, and
S J Russell
October 1999,
Current opinion in molecular therapeutics,
B H Nilson, and
F J Morling, and
F L Cosset, and
S J Russell
January 2003,
Current topics in microbiology and immunology,
B H Nilson, and
F J Morling, and
F L Cosset, and
S J Russell
July 1995,
Science (New York, N.Y.),
B H Nilson, and
F J Morling, and
F L Cosset, and
S J Russell
April 1998,
Human gene therapy,
B H Nilson, and
F J Morling, and
F L Cosset, and
S J Russell
June 1998,
Critical reviews in oncology/hematology,
B H Nilson, and
F J Morling, and
F L Cosset, and
S J Russell
April 1993,
Human gene therapy,
B H Nilson, and
F J Morling, and
F L Cosset, and
S J Russell
May 2003,
Human gene therapy,
B H Nilson, and
F J Morling, and
F L Cosset, and
S J Russell
January 1994,
Revue roumaine de virologie (Bucharest, Romania : 1990),
